Bellicum Pharmaceuticals, Inc. BLCM, a clinical stage
biopharmaceutical company focused on discovering and developing novel cellular
immunotherapies, today announced that the first cohort of patients in the
BP-004 trial has completed dosing with the Company's genetically engineered
donor T cells (BPX-501), after receiving a partial T depleted haplo-identical
allogeneic hematopoietic stem cell transplant (haplo-HSCT).
The trial in pediatric patients is evaluating whether BPX-501 T cells from
partially mis-matched donors administered following HSCT are safe and can help
speed immune reconstitution. BPX-501 contains the CaspaCIDe^® safety switch,
giving doctors the ability to eliminate the T cells should they cause
Graft-versus-host disease, a more common occurrence with a haplo-HSCT than
with a matched procedure. BPX-501 is designed to allow study doctors to
restore patient immunity earlier with increasingly higher doses of
haplo-identical T cells, in an effort to improve infection control and overall
transplant outcomes.
“For hematological cancers and many orphan blood disorders such as severe
primary immune deficiencies, inherited bone marrow failure syndromes,
thalassemia and sickle cell disease, a hematopoietic stem cell transplant from
a matched donor has resulted in a lifetime cure. But many patients lack a
suitable, matched donor, eliminating this option,” said Prof. Francesco
Locatelli, MD, lead study investigator and Full Professor of Pediatrics,
University of Pavia, and Director, Department of Pediatric Hematology and
Oncology, IRCCS Pediatrico Bambino Gesù Piazza, Rome, Italy. “Making
haplo-identical transplants safer and more effective could make this curative
therapy available to many times the number of patients eligible today.”
Commented Bellicum CEO Tom Farrell, “We're pleased to have successfully
launched a clinical program acceptable to U.S. and European regulatory
agencies that allows us to include patients with blood cancers and up to 18
different non-malignant blood diseases under a single protocol. We believe
BPX-501 may have the potential to make alternative donor haplo-identical stem
cell transplants as routine as conventional transplants from matched donors,
enabling a treatment known to be curative, and making it available for many
more patients suffering from a wide range of deadly and life-long diseases.”
Study Details
The ongoing BP-004 trial is a Phase 1 / 2 multi-center, open label dose
escalation study being held at leading transplant centers in Europe and in the
U.S. The Phase 1 arm consists of three cohorts of three to six patients, each
receiving escalating doses of BPX-501 T cells following haplo-HSCT. A Phase 2
extension arm will use the highest tolerated Phase 1 dose, with a maximum of
30 patients in both phases. The trial is enrolling pediatric patients, ages
three months to 21 years, diagnosed with blood cancers^(1), immune
deficiencies^(2) or inherited hematologic disorders^(3), where hematopoietic
stem cell transplants are historically curative.
The trial will also evaluate the treatment of Graft-versus-host disease (GvHD)
in transplant patients who have received BPX-501 by infusion of the small
molecule, dimerizer drug rimiducid (formerly AP1903). Rimiducid is designed to
trigger rapid apoptosis and elimination of allo-reactive T cells. Patients who
develop Grade III-IV acute GvHD, Grade II gut/liver GvHD, or Grade I-II acute
GvHD (skin only) who progress or do not respond to standard treatment, will
receive rimiducid.
Primary study endpoints include safety and optimal dosing of BPX-501 T cells,
safety of rimiducid infusion in those patients who receive it to trigger
elimination of BPX-501 T cells, and time to immune reconstitution. Primary
endpoints for the Phase 2 extension also includes cumulative incidence of
non-relapse mortality at 180 days and one year.
^(1) Hematologic cancers include leukemias and lymphomas
^(2) Immune deficiencies include severe combined immunodeficiency (SCID
disorders), common variable immunodeficiency, alymphocytosis (“boy in a
bubble” disease) and others
^(3) Inherited hematological disorders include hemoglobinopathies including
sickle cell, thalassemia, Fanconi's anemia, and others.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: NewsPress Releases
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in